- Email: [email protected]
Jarvik 2000: Long Term Results and Quality of Life
to investigate whether a trend towards bioprosthetic AVR exists in adults aged 65 and under at our studied tertiary centre over a seven year period. As a secondary objective, this trend was investigated in adults of all ages. Methods: Patients who underwent first time AVR using mechanical or bioprosthetic valves between 1st January 2004 and 31st December 2010 were identified in the Wesley Hospital cardiac surgery database. Excluding active endocarditis, anticoagulation use, dialysis dependent patients, 663 patients remained with 198 patients aged 65 and under. The trend was examined by comparing the proportion of bioprosthetic use in 2004 and 2010 using Chi-square analysis.
Results: There was no significant difference in proportion of bioprosthetic use between 2004 and 2010 in patients aged 65 years and under (p-value = 0.256), and in adults of all ages (p-value = 0.778). Across the sevenyear period, 40.4% of AVR were bioprosthetic valves from 2004 to 2010 in the 65 years and under group, while 77.4% were bioprosthetic valves in the all ages group. Conclusion: Despite improvements in the field of bioprosthetic AVR, we did not identify a trend towards bioprosthesis use. http://dx.doi.org/10.1016/j.hlc.2012.05.681 671 Jarvik 2000: Long Term Results and Quality of Life E. Buratto ∗ , V. Tarzia, T. Bottio, G. Gerosa Division of Cardiac Surgery, Department of Cardiac, Thoracic and Vascular Sciences, Università degli Studi di Padova, Italy Background: The Jarvik-2000 is an axial-flow-pump with a percutaneous retro-auricular power connector, designed for long-term use. We sought to evaluate the outcomes and quality of life of patients with continuous-support with the Jarvik-2000 left-ventricular-assist-device.
Abstracts CSANZ 2012 Abstracts
S279
Methods: Between December 2008 and March 2012, we implanted Jarvik-2000 in 10 patients (mean age 66.2 ± 5.5 years, median 67). Of the 10 patients, nine were male. All were NYHA IV with ischaemic (n = 5) or idiopathic dilated (n = 5) cardiomyopathy. The mechanical circulatory support was intended as destination-therapy in nine patients, and as bridge-to-transplantation in one patient. In addition to standard coagulation analysis, we used functional coagulation tests including a thrombelastographic-monitoring-system (ROTEM) and a platelet function analyzer (MULTIPLATE) to calibrate the multidrug-antithrombotic-therapy. Functional-status (NYHA functional class, 6-min walk distance) and quality of life (SF-36) were assessed after LVAD implantation. Results: Mean time of all patients on LVAD support was 450.4 ± 429.3 days, while mean time on support for
patients discharged from hospital (70%) was 634.6 ± 80.2 days. Early mortality was 30%. The three early deaths were due to right ventricular failure and sepsis. There were two late deaths, both due to sepsis. There were no disabling strokes, no neurological deaths due to haemorrhagic or thrombotic events and no pump malfunction. Functional status and quality of life improved after LVAD implantation. Conclusions: Expert antithrombotic-therapy management clearly allows prolonged event-free-survival in these patients. The Jarvik-2000 might prove a valid option for the long-term treatment of patients with severe heart failure bringing improved functional-status and quality of life. http://dx.doi.org/10.1016/j.hlc.2012.05.682
ABSTRACTS
Heart, Lung and Circulation 2012;21:S143–S316
Results: There was no significant difference in proportion of bioprosthetic use between 2004 and 2010 in patients aged 65 years and under (p-value = 0.256), and in adults of all ages (p-value = 0.778). Across the sevenyear period, 40.4% of AVR were bioprosthetic valves from 2004 to 2010 in the 65 years and under group, while 77.4% were bioprosthetic valves in the all ages group. Conclusion: Despite improvements in the field of bioprosthetic AVR, we did not identify a trend towards bioprosthesis use. http://dx.doi.org/10.1016/j.hlc.2012.05.681 671 Jarvik 2000: Long Term Results and Quality of Life E. Buratto ∗ , V. Tarzia, T. Bottio, G. Gerosa Division of Cardiac Surgery, Department of Cardiac, Thoracic and Vascular Sciences, Università degli Studi di Padova, Italy Background: The Jarvik-2000 is an axial-flow-pump with a percutaneous retro-auricular power connector, designed for long-term use. We sought to evaluate the outcomes and quality of life of patients with continuous-support with the Jarvik-2000 left-ventricular-assist-device.
Abstracts CSANZ 2012 Abstracts
S279
Methods: Between December 2008 and March 2012, we implanted Jarvik-2000 in 10 patients (mean age 66.2 ± 5.5 years, median 67). Of the 10 patients, nine were male. All were NYHA IV with ischaemic (n = 5) or idiopathic dilated (n = 5) cardiomyopathy. The mechanical circulatory support was intended as destination-therapy in nine patients, and as bridge-to-transplantation in one patient. In addition to standard coagulation analysis, we used functional coagulation tests including a thrombelastographic-monitoring-system (ROTEM) and a platelet function analyzer (MULTIPLATE) to calibrate the multidrug-antithrombotic-therapy. Functional-status (NYHA functional class, 6-min walk distance) and quality of life (SF-36) were assessed after LVAD implantation. Results: Mean time of all patients on LVAD support was 450.4 ± 429.3 days, while mean time on support for
patients discharged from hospital (70%) was 634.6 ± 80.2 days. Early mortality was 30%. The three early deaths were due to right ventricular failure and sepsis. There were two late deaths, both due to sepsis. There were no disabling strokes, no neurological deaths due to haemorrhagic or thrombotic events and no pump malfunction. Functional status and quality of life improved after LVAD implantation. Conclusions: Expert antithrombotic-therapy management clearly allows prolonged event-free-survival in these patients. The Jarvik-2000 might prove a valid option for the long-term treatment of patients with severe heart failure bringing improved functional-status and quality of life. http://dx.doi.org/10.1016/j.hlc.2012.05.682
ABSTRACTS
Heart, Lung and Circulation 2012;21:S143–S316